167 related articles for article (PubMed ID: 31450280)
21. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
Gandhi M; Alwawi E; Gordon KB
Semin Cutan Med Surg; 2010 Mar; 29(1):48-52. PubMed ID: 20430307
[TBL] [Abstract][Full Text] [Related]
22. New and emerging therapies in psoriasis.
Leonardi CL; Gordon KB
Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S37-41. PubMed ID: 24979544
[TBL] [Abstract][Full Text] [Related]
23. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M; Rudnicka L; Olszewska M
Am J Clin Dermatol; 2011 Apr; 12(2):113-25. PubMed ID: 21348542
[TBL] [Abstract][Full Text] [Related]
24. Frontal fibrosing alopecia: possible association with leave-on facial skin care products and sunscreens; a questionnaire study.
Aldoori N; Dobson K; Holden CR; McDonagh AJ; Harries M; Messenger AG
Br J Dermatol; 2016 Oct; 175(4):762-7. PubMed ID: 26987767
[TBL] [Abstract][Full Text] [Related]
25. Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab.
Nakayama C; Fujita Y; Watanabe M; Shimizu H
J Dermatol; 2015 Oct; 42(10):996-8. PubMed ID: 26010891
[TBL] [Abstract][Full Text] [Related]
26. Adverse Reactions to Biologics in Psoriasis.
Lockwood SJ; Prens LM; Kimball AB
Curr Probl Dermatol; 2018; 53():1-14. PubMed ID: 29131033
[TBL] [Abstract][Full Text] [Related]
27. Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy.
Gutiérrez-González E; Batalla A; de la Mano D
Dermatol Online J; 2014 Apr; 20(4):22338. PubMed ID: 24746301
[TBL] [Abstract][Full Text] [Related]
28. Concurrent treatment of chronic psoriasis and asthma with ustekinumab.
Amarnani A; Rosenthal KS; Mercado JM; Brodell RT
J Dermatolog Treat; 2014 Feb; 25(1):63-6. PubMed ID: 23469809
[TBL] [Abstract][Full Text] [Related]
29. Briakinumab for the treatment of plaque psoriasis.
Traczewski P; Rudnicka L
BioDrugs; 2012 Feb; 26(1):9-20. PubMed ID: 22077474
[TBL] [Abstract][Full Text] [Related]
30. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
[TBL] [Abstract][Full Text] [Related]
31. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
32. Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab.
Dickson L; Menter A
J Drugs Dermatol; 2017 Feb; 16(2):177-179. PubMed ID: 28300862
[TBL] [Abstract][Full Text] [Related]
33. Cutaneous protothecosis in a patient on ustekinumab for psoriasis.
Jenkinson H; Thelin L; McAndrew R; Jones KM; Talbott LB; Diven D
Int J Dermatol; 2018 Oct; 57(10):1246-1248. PubMed ID: 29603193
[No Abstract] [Full Text] [Related]
34. The efficacy of ustekinumab in psoriasis.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Mar; 12(3):317-20. PubMed ID: 23545915
[TBL] [Abstract][Full Text] [Related]
35. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
Jemec GB; Ibler KS
J Drugs Dermatol; 2012 Aug; 11(8):939-42. PubMed ID: 22859238
[TBL] [Abstract][Full Text] [Related]
36. Interstitial pneumonia in two patients with psoriasis during ustekinumab treatment.
Kikuchi S; Umezawa Y; Hayashi M; Yanaba K; Fukuchi O; Ito T; Asahina A; Saeki H; Nakagawa H
J Dermatol; 2016 Jun; 43(6):712-3. PubMed ID: 26703791
[No Abstract] [Full Text] [Related]
37. Data on the safety of psoriasis therapies.
Leonardi CL
Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S73-5. PubMed ID: 25268600
[TBL] [Abstract][Full Text] [Related]
38. Wells' Syndrome Induced by Ustekinumab.
Rozenblat M; Cohen-Barak E; Dodiuk-Gad R; Ziv M
Isr Med Assoc J; 2019 Jan; 21(1):65. PubMed ID: 30685913
[No Abstract] [Full Text] [Related]
39. IL-12/IL-23 inhibitors: the advantages and disadvantages of this novel approach for the treatment of psoriasis.
Bartlett BL; Moody MN; Tyring SK
Skin Therapy Lett; 2008; 13(8):1-4. PubMed ID: 19145382
[TBL] [Abstract][Full Text] [Related]
40. Frontal fibrosing alopecia with involvement of the central hair part: distribution of hair loss corresponding to areas of sunscreen application.
Mirmirani P; Vanderweil SG
Dermatol Online J; 2020 Nov; 26(11):. PubMed ID: 33342178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
